Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …

Chronic graft-versus-host disease (GVHD) is the leading cause of late morbidity and
mortality after allogeneic hematopoietic cell transplantation. Symptoms and manifestations …

Clinical research into chronic graft-versus-host disease (GVHD) lags behind that in other
areas in the field. Interest in chronic GVHD has increased significantly in recent years for …

Despite improvements in the practice of allogeneic hematopoietic stem cell transplantation
(HCT) over the last 25 years, chronic graft-versus-host disease (GVHD) remains a …

With the increasing use of mismatched, unrelated, and granulocyte colony-stimulating factor–
mobilized peripheral blood stem cell donor grafts and successful treatment of older …

Chronic graft-versus-host-disease (cGVHD) is a major barrier to successful allogeneic
hematopoietic stem cell transplantation (allo-HSCT), with highly variable clinical …

Chronic graft-versus-host disease (GVHD) has been a difficult problem to address and
clinical research in this area lags behind other innovations in hematopoietic stem cell …

Clinical outcomes for patients undergoing allogeneic hematopoietic stem cell
transplantation continue to improve, but chronic graft-versus-host disease (GVHD) remains a …

Biology-based markers that can be used to confirm the diagnosis of chronic graft-versus-
host disease (GVHD) or monitor progression of the disease could help in the evaluation of …

Recognition of the earliest signs and symptoms of chronic graft-versus-host disease (GVHD)
that lead to severe manifestations remains a challenge. The standardization provided by the …